Naltrexone LA is under clinical development by BioCorRx and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Naltrexone LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Naltrexone LA overview
Naltrexone is under development for the treatment of alcohol, opioid addiction and methamphetamine use disorder (MUD). It is a long acting implantable naltrexone implant, administered by the subcutaneous route. It acts by targeting mu type opioid receptor.
See Also:
BioCorRx overview
BioCorRx is a healthcare solution provider that offers treatment for substance use and other related disorders. The company offers alcoholism and opioid addiction treatment programs for use in rehabilitation and treatment centers. It distributes and licenses the BioCorRx recovery program, a medication-assisted treatment (MAT) program that includes a counseling program coupled with its proprietary naltrexone implant. It also develops BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics and licensed healthcare professionals. BioCorRx is headquartered in Anaheim, California, the US.
For a complete picture of Naltrexone LA’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
